SCHEMBL7907727

SCHEMBL7907727

O=C(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(C(=O)NNc2ccccc2)(c2ccc(F)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 2/20 0.50
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
HSD11B1 P28845 2/20 0.48
TSHR P16473 1/20 0.47
PTPN1 P18031 1/20 0.45
FASN P49327 3/20 0.45
PRKAA2 P54646 2/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
USP2 O75604 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3107003 0.94 PTPN1 (0.50) SLC6A7KMT2AMEN1HSD11B1TSHR
SCHEMBL3227686 0.91 CYP3A4 (0.48) SLC6A7KMT2AMEN1TSHRPTPN1
SCHEMBL7900928 0.89 PTPN1 (0.46) SLC6A7KMT2AMEN1HSD11B1TSHR
SCHEMBL3110203 0.89 HSP90AA1 (0.47) HSD11B1PTPN1FASNPRKAA2CA12
SCHEMBL13102505 0.88 HDAC1 (0.43) SLC6A7KMT2AMEN1HSD11B1TSHR
SCHEMBL3106971 0.86 PTPN1 (0.45) SLC6A7KMT2AMEN1HSD11B1TSHR
SCHEMBL3092523 0.85 CYP3A4 (0.51) SLC6A7KMT2AMEN1TSHRPRKAA2
SCHEMBL13092423 0.85 SLC6A7 (0.50) SLC6A7KMT2AMEN1HSD11B1TSHR
SCHEMBL3092755 0.81 KMT2A (0.59) SLC6A7KMT2AMEN1HSD11B1TSHR
SCHEMBL3092692 0.81 FASN (0.48) SLC6A7KMT2AMEN1HSD11B1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 SLC6A7 105/4885KMT2A 1488/4885MEN1 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.